MGZL Therapy Option

MGZL Therapy Option

Mediastinal gray zone lymphoma (MGZL) is very rare with indeterminate pathology. In addition, the clinical characteristics of, and the treatment…

More...
Treatment Option for WM

Treatment Option for WM

In a multicentre phase II study undertaken in Germany, the safety and efficacy of pentostatin, cyclophosphamide and rituximab (PER) were…

More...
MCL and Radiation Therapy

MCL and Radiation Therapy

While chemotherapy is the basis of treatment in mantle cell lymphoma (MCL), radiotherapy is not often used. In this retrospective…

More...
Stop Lymphoma

Stop Lymphoma

Thanks to everyone who participated in World Lymphoma Awareness Day by helping raise public awareness of lymphoma globally. In recognition…

More...
Frontpage Slideshow | Copyright © 2006-2011 JoomlaWorks Ltd.

Healthcare Matters

  • 1
  • 2
  • 3
Prev Next

Hope for Peripheral T-cell Lymphoma

Peripheral T-cell lymphomas (PTCL) are rare and heterogeneous lymphomas comprising numerous histologies. Given the rarity and number of these lymphomas, the tendency has been to group them as one entity. For decades they have been treated in much the same way as B-cell lymphomas using conventional chemotherapy resulting in poor long-term survival.

Read more

A Peek at AIL (Italy)

For the last 20 years, Maria Rita Grattarola has been involved with the Italian Association against leukemia-lymphoma and myeloma (AIL). Prior to joining AIL, Maria Rita was a business teacher. Initially, she volunteered for AIL and over the 20 years Maria Rita has been involved with the organisation, she has worked in many different areas. For the last 10 years, she’s been mostly responsible for organising patient seminars and patient groups.

Read more

Leukaemia & Blood Cancer New Zealand

Being a chief executive officer (CEO) comes with many responsibilities as Pru Etcheverry, CEO of Leukaemia & Blood Cancer New Zealand (LBC), can attest. “Every day is different but key responsibilities are income generation and financial management, leadership, brand building and positioning, service delivery for patients and families, and looking at organisational sustainability,” said Pru.

Read more

Latest Lymphoma News

  • Improved Survival in Europe

    Findings from a retrospective observational study that included patients diagnosed with haematological malignancies from 20 European countries showed that survival increased for most haematological malignancies.


    Read more...
  • Downside of Rural Living

    Patients with cancer who live in a rural location in Australia are more likely to die than those living in an urban centre because they cannot access needed radiotherapy treatment.


    Read more...

What's Happening Around the World

  • A Peek at the IWMF

    This is the second in a series of articles examining the work undertaken by patient organisations to help those affected by WM.

    Waldenstrom’s macroglobulinaemia (WM) is a rare, slow growing blood cancer. Approximately three in one million people are diagnosed with WM every year in the USA. In Europe, approximately five in one million people are diagnosed with WM each year. WM is classified as an orphan disease, i.e., one so rare that funds for research and enough patients for clinical trials are scarce. Treatment options for WM are often based on research undertaken in other disorders.

    Read more...  
  • A Peek at the European EWMnetwork

    This is the first in a series of articles examining the work undertaken by patient organisations to help those affected by WM.  Waldenstrom’s macroglobulinaemia (WM) is a rare, slow growing blood cancer. Approximately three in one million people are diagnosed with WM every year in the USA.

    Read more...  

Research

  • Real World Data on PTCL

    To complement retrospective analyses of clinical trials, an analysis of prognostic factors and outcomes in an unselected population-based cohort of patients with peripheral T-cell lymphoma (PTCL) was undertaken.

    Read more...  
  • Prognostic Index for CLL

    A number of biomarkers have been identified as being predictors of overall survival in chronic lymphocytic leukaemia (CLL). However, given that there are numerous biomarkers with inadequate information regarding their prognostic value

    Read more...  

 
The information on this website is for general use only. Please consult your physician if you think you may have lymphoma or require more detailed information on the best course of treatment for you.

Global Database Search

IN THE NODE

Updates